Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up. - Abstract - Europe PMC
Hepcvel Ayurvedic Sirolimus Tablets, for Anti-Infective, Gel
Keratosis pilaris rubra successfully treated with topical sirolimus: Report of a case and review of the literature - Eckburg - 2022 - Pediatric Dermatology - Wiley Online Library
New Breakthrough in Treatment for Rare Skin Condition - ResOU
Sirolimus - Wikipedia
Use of topical rapamycin in facial angiofibromas in Indian skin type
First Topical Therapy for Facial Angiofibroma Nabs FDA Approval | MedPage Today
Frontiers | Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex
Sirolimus Tablets - Sirolimus siroboon 1 mg 100% Export Oriented Unit from Faridabad
About HYFTOR - HYFTOR® Patient Site
Nobelpharma America on X: "We're excited to announce that HYFTOR™ (sirolimus topical gel) 0.2% is now approved by the FDA! Learn more: https://t.co/VonIUt4ZVi https://t.co/P1WjZ6J4Xs" / X
Figure 3 from Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex | Semantic Scholar
HYFTOR™ (sirolimus topical gel) 0.2%, the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis, is now available in the US
Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: Follow up of a pilot study and promising future directions - Tu - 2014 - Australasian Journal of Dermatology - Wiley Online Library
HYFTOR Dosage & Rx Info | Uses, Side Effects
Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect
These highlights do not include all the information needed to use HYFTOR™ safely and effectively. See full prescribing information for HYFTOR. HYFTOR™ (sirolimus topical gel) Initial U.S. Approval: 1999
Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex: A Randomized Clinical Trial | Semantic Scholar
Learn more at www.HYFTOR.com
Home - HYFTOR® HCP Site
Sirolimus gel provides breakthrough treatment for TSC
Hyftor (Sirolimus): Dosage, Uses, Side Effects & Reviews
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy
Home - HYFTOR® Patient Site
![PDF] Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/54f9e54723a39a55b43d74e366e743df79c21bd7/6-Figure3-1.png "PDF] Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial | Semantic Scholar")